home / stock / drug:cc / drug:cc news

DRUG:CC News and Press, Bright Minds Biosciences Inc.

Stock Information
Company Name: Bright Minds Biosciences Inc.
Stock Symbol: DRUG:CC
Market: CNQC
Website: brightmindsbio.com
Menu
DRUG:CC DRUG:CC Quote DRUG:CC Short DRUG:CC News DRUG:CC Articles DRUG:CC Message Board
Get DRUG:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
DRUG:CC - Canadian Companies Moving the Markets, Evening edition
Tue, Apr 30, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Ivanhoe Mines Ltd. (IVN) fell 9.6% to $18.64 on volume of 19,471,224 shares Canopy Growth Corporation (WEED) rose 78.2% to $20.24 on volume of 19,456,911 shares Enbridge Inc. (ENB) fell 0.4% to $48.95 on volume of 18,616,928 shares Tilray Bran...
DRUG:CC - Canadian Companies Moving the Markets, Evening edition
Tue, Mar 26, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Auxly Cannabis Group Inc. (XLY) rose 100.0% to $0.06 on volume of 25,275,816 shares Canopy Growth Corporation (WEED) rose 15.2% to $9.8 on volume of 18,760,847 shares Toronto-Dominion Bank (The) (TD) rose 0.1% to $81.04 on volume of 18,116,348 s...

DRUG:CC - Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITE...

DRUG:CC - Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascend...
DRUG:CC - Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascendin...

DRUG:CC - CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every five (5) pre-consolidated common shares. As a result, the outs...

DRUG:CC - Bright Minds Announces Effective Date of Share Consolidation

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatr...
DRUG:CC - Bright Minds Announces Proposed Share Consolidation

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatr...

DRUG:CC - Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

-- BMB-202 is a highly selective 5-HT 2A agonist that exhibits a more than 30-fold selectivity over 5-HT 2C and more than 500-fold selectivity over 5-HT 2B -- -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT 2A and 5-HT 2A/2C agoni...

DRUG:CC - Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

— Presentation entitled "BMB-101: A selective 5-HT 2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 20...
Next 10